Aviragen Therapeutics (AVIR) Reports Q4 Loss of $0.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St futures subdued as Nvidia results, inflation take center stage
- Oil drops to more than two-week low on hopes of Hormuz reopening
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
August 31, 2017 4:01 PM EDTATLANTA, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ: AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017.
We have made great strides, working with our Board and financial advisors, in honing in on a select number of strategic alternatives, commented Joseph M. Patti, PhD, President and Chief Executive Officer of Aviragen Therapeutics. Importantly, we have also taken actions to minimize cash spending in order to maintain the Companys solid financial position as evidenced by our reported cash position of $38.6 million.
... More